PE20210404A1 - Derivados de pirrolo [1,2-b] piridazina - Google Patents
Derivados de pirrolo [1,2-b] piridazinaInfo
- Publication number
- PE20210404A1 PE20210404A1 PE2021000046A PE2021000046A PE20210404A1 PE 20210404 A1 PE20210404 A1 PE 20210404A1 PE 2021000046 A PE2021000046 A PE 2021000046A PE 2021000046 A PE2021000046 A PE 2021000046A PE 20210404 A1 PE20210404 A1 PE 20210404A1
- Authority
- PE
- Peru
- Prior art keywords
- pirrolo
- pyridazine
- derivatives
- methyl
- kinase
- Prior art date
Links
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 102000000589 Interleukin-1 Human genes 0.000 abstract 1
- 108010002352 Interleukin-1 Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto de formula (II) o una sal farmaceuticamente aceptable o isomero estructural del mismo, donde: R1 es H, D o metilo; R2 es H, D o metilo; o R1 y R2, junto con los atomos de carbono a los que estan unidos, forman ciclopropilo. Tambien esta referida a composiciones de los mismos. Dichos compuestos son inhibidores de la quinasa Interleucina-1 asociada a la quinasa-4 (IRAK4)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862697533P | 2018-07-13 | 2018-07-13 | |
| PCT/US2019/041382 WO2020014468A1 (en) | 2018-07-13 | 2019-07-11 | Pyrrolo[1,2-b] pyridazine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210404A1 true PE20210404A1 (es) | 2021-03-02 |
Family
ID=67480334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000046A PE20210404A1 (es) | 2018-07-13 | 2019-07-11 | Derivados de pirrolo [1,2-b] piridazina |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10875866B2 (es) |
| EP (2) | EP3820872B1 (es) |
| JP (3) | JP7167298B2 (es) |
| KR (2) | KR20230144100A (es) |
| CN (2) | CN117683034A (es) |
| AR (1) | AR115731A1 (es) |
| AU (3) | AU2019302732B2 (es) |
| BR (1) | BR112020026675A2 (es) |
| CA (1) | CA3105485C (es) |
| CL (1) | CL2021000086A1 (es) |
| CO (1) | CO2021000153A2 (es) |
| CR (1) | CR20210014A (es) |
| DK (1) | DK3820872T3 (es) |
| EA (1) | EA202092858A1 (es) |
| ES (1) | ES2981798T3 (es) |
| FI (1) | FI3820872T3 (es) |
| HR (1) | HRP20240811T8 (es) |
| IL (2) | IL279654B2 (es) |
| LT (1) | LT3820872T (es) |
| MX (2) | MX2021000462A (es) |
| NZ (1) | NZ771681A (es) |
| PE (1) | PE20210404A1 (es) |
| PH (1) | PH12020552283A1 (es) |
| PL (1) | PL3820872T3 (es) |
| PT (1) | PT3820872T (es) |
| SG (1) | SG11202013003VA (es) |
| SI (1) | SI3820872T1 (es) |
| TW (2) | TWI842978B (es) |
| UA (1) | UA127506C2 (es) |
| WO (1) | WO2020014468A1 (es) |
| ZA (1) | ZA202100259B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI842978B (zh) * | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| CN115698010A (zh) * | 2020-06-10 | 2023-02-03 | 赛克松公司 | 用于制备结晶形式的rabeximod的方法 |
| JP2024531273A (ja) | 2021-08-18 | 2024-08-29 | ニューリックス セラピューティクス，インコーポレイテッド | インターロイキン－１受容体関連キナーゼの二官能性分解剤及びその治療的使用 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002332099B2 (en) | 2001-10-09 | 2007-12-13 | Amgen Inc. | Imidazole derivates as antiinflammatory agents |
| US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| WO2008016643A2 (en) | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| KR20090049076A (ko) | 2006-09-07 | 2009-05-15 | 바이오겐 아이덱 엠에이 인코포레이티드 | 인터루킨-1 수용체-결합 키나제 조절물질로서 인다졸 유도체 |
| JP5107660B2 (ja) | 2007-03-28 | 2012-12-26 | 太平洋セメント株式会社 | セメント添加材及びセメント組成物 |
| DE102009033208A1 (de) | 2009-07-15 | 2011-01-20 | Merck Patent Gmbh | Aminopyridinderivate |
| JP2013501003A (ja) | 2009-07-31 | 2013-01-10 | バイオクライスト ファーマシューティカルズ， インコーポレイテッド | ヤヌスキナーゼ阻害剤としてのピロロ［１，２−ｂ］ピリダジン誘導体 |
| JP2012254939A (ja) | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
| CN105367577B (zh) | 2010-07-13 | 2019-04-23 | 弗·哈夫曼-拉罗切有限公司 | 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物 |
| MX366318B (es) | 2010-11-19 | 2019-07-05 | Ligand Pharm Inc | Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1. |
| CN103429585B (zh) | 2010-12-20 | 2015-07-08 | 默克雪兰诺股份有限公司 | 作为白细胞介素-1受体相关激酶抑制剂的吲唑基三唑衍生物 |
| US8703941B2 (en) | 2011-01-10 | 2014-04-22 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
| WO2012129258A1 (en) | 2011-03-22 | 2012-09-27 | Merck Sharp & Dohme Corp. | Amidopyrazole inhibitors of interleukin receptor-associated kinases |
| WO2013042137A1 (en) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| US9221809B2 (en) | 2011-10-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
| BR112014010938A2 (pt) | 2011-11-09 | 2017-05-16 | Cancer Res Tech Ltd | compostos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrila e seu uso terapêutico |
| EP2802330A4 (en) | 2012-01-10 | 2015-10-21 | Nimbus Iris Inc | IRAQ INHIBITORS AND USES THEREOF |
| ES2575604T3 (es) | 2012-01-13 | 2016-06-29 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa |
| CN104169275B (zh) | 2012-01-13 | 2017-06-09 | 百时美施贵宝公司 | 用作激酶抑制剂的三唑取代的吡啶化合物 |
| JP6109195B2 (ja) | 2012-01-13 | 2017-04-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | キナーゼ阻害剤として有用な複素環置換されたピリジル化合物 |
| AU2013289615B2 (en) | 2012-07-10 | 2017-06-08 | Ares Trading S.A. | Pyrimidine pyrazolyl derivatives |
| EP2872144A4 (en) | 2012-07-11 | 2015-12-02 | Nimbus Iris Inc | IRAQ INHIBITOR AND USES THEREOF |
| JP2015528801A (ja) | 2012-07-11 | 2015-10-01 | ニンバス アイリス， インコーポレイテッド | Ｉｒａｋ阻害剤およびその使用 |
| US20140018361A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2014058685A1 (en) | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| WO2014058691A1 (en) | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| SG11201503397YA (en) | 2012-11-08 | 2015-05-28 | Bristol Myers Squibb Co | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| US9546153B2 (en) | 2012-11-08 | 2017-01-17 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
| AU2013341195B2 (en) | 2012-11-08 | 2017-09-21 | Bristol-Myers Squibb Company | Alkyl amide-substituted pyrimidine compounds useful in the modulation of IL-12, IL-23 and/or IFNalpha |
| US9505748B2 (en) | 2012-11-08 | 2016-11-29 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses |
| BR112015011456A2 (pt) | 2012-11-20 | 2017-07-11 | Genentech Inc | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m |
| US9175007B2 (en) | 2013-01-10 | 2015-11-03 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
| MX364486B (es) | 2013-02-07 | 2019-04-29 | Merck Patent Gmbh | Derivados de piridazinona-amidas. |
| HUE035919T2 (en) | 2013-02-07 | 2018-05-28 | Merck Patent Gmbh | Macrocyclic pyridazinone derivatives |
| WO2014143672A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases |
| WO2014210354A1 (en) | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| US20160166576A1 (en) | 2013-07-11 | 2016-06-16 | Merck Sharp & Dohme Corp. | Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4) |
| RU2016110852A (ru) | 2013-09-27 | 2017-10-30 | Нимбус Айрис, Инк. | Ингибиторы irak и их применения |
| JP6412148B2 (ja) | 2013-11-08 | 2018-10-24 | 武田薬品工業株式会社 | 自己免疫疾患治療のためのピラゾール |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| UY35935A (es) | 2014-01-03 | 2015-06-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4 |
| US10314841B2 (en) | 2014-01-09 | 2019-06-11 | Merck Patent Gmbh | Substituted pyrazoles as IRAK inhibitors |
| SG11201605408RA (en) | 2014-01-10 | 2016-07-28 | Aurigene Discovery Tech Ltd | Indazole compounds as irak4 inhibitors |
| LT3466955T (lt) | 2014-01-13 | 2021-02-25 | Aurigene Discovery Technologies Limited | Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas |
| UA121467C2 (uk) | 2014-04-04 | 2020-06-10 | Пфайзер Інк. | Біциклічні анельовані гетероарильні або арильні сполуки та їх застосування як інгібіторів irak4 |
| US20150329498A1 (en) | 2014-04-22 | 2015-11-19 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| JP2017518348A (ja) | 2014-06-20 | 2017-07-06 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | Ｉｒａｋ４阻害剤としての置換インダゾール化合物 |
| AR101229A1 (es) | 2014-07-18 | 2016-11-30 | Biogen Ma Inc | Agentes inhibidores de irak4 |
| EP3200789B1 (en) | 2014-09-30 | 2019-11-06 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| WO2016053771A1 (en) | 2014-09-30 | 2016-04-07 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| US9926330B2 (en) | 2014-09-30 | 2018-03-27 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| US9943516B2 (en) | 2014-09-30 | 2018-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
| ES2772133T3 (es) | 2014-11-20 | 2020-07-07 | Merck Patent Gmbh | Compuestos heteroarilo como inhibidores de IRAK y sus usos |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| SG11201704628VA (en) | 2015-02-05 | 2017-07-28 | Merck Patent Gmbh | Macrocyclic compounds as irak1/4 inhibitors and uses thereof |
| SG11201704651UA (en) | 2015-02-06 | 2017-07-28 | Merck Patent Gmbh | Pyridazinone macrocycles as irak inhibitors and uses thereof |
| US10155765B2 (en) | 2015-03-12 | 2018-12-18 | Merck Sharp & Dohme Corp. | Carboxamide inhibitors of IRAK4 activity |
| EP3268003B1 (en) | 2015-03-12 | 2020-07-29 | Merck Sharp & Dohme Corp. | Thienopyrazine inhibitors of irak4 activity |
| WO2016144848A1 (en) | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Pyrrolotriazine inhibitors of irak4 activity |
| EP3268004B1 (en) | 2015-03-12 | 2019-12-18 | Merck Sharp & Dohme Corp. | Pyrrolopyridazine inhibitors of irak4 activity |
| WO2016144846A1 (en) | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of irak4 activity |
| PE20180118A1 (es) | 2015-04-22 | 2018-01-18 | Rigel Pharmaceuticals Inc | Compuestos de pirazol y metodo para elaborar y usar los compuestos |
| CA2984259C (en) | 2015-04-30 | 2024-02-13 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| AR105112A1 (es) | 2015-06-24 | 2017-09-06 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituida con heteroarilo |
| JP6843775B2 (ja) | 2015-06-24 | 2021-03-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロアリール置換のアミノピリジン化合物 |
| AR105114A1 (es) | 2015-06-24 | 2017-09-06 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituida con heteroarilo |
| WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2017004133A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| JP2018524365A (ja) | 2015-07-15 | 2018-08-30 | アウリジーン ディスカバリー テクノロジーズ リミテッド | Ｉｒａｋ−４阻害剤としての置換アザ化合物 |
| BR112018000624A2 (pt) | 2015-07-15 | 2018-09-18 | Aurigene Discovery Technologies Limited | compostos de indazol e azaindazol como inibidores de irak-4 |
| JP7083309B2 (ja) | 2015-08-04 | 2022-06-10 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム エルティーディー． | ピラゾールピリミジン誘導体及びその使用 |
| JP6994454B2 (ja) | 2015-08-04 | 2022-01-14 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ベンズアゾール化合物ならびに該化合物の作製方法および使用方法 |
| BR112018002071A2 (pt) | 2015-08-13 | 2018-09-18 | Pfizer | compostos heteroarílicos ou arílicos fundidos bicíclicos |
| JP6541871B2 (ja) | 2015-08-13 | 2019-07-10 | 北京韓美薬品有限公司 | Ｉｒａｋ４阻害剤、及びその応用 |
| CN107531725B (zh) | 2015-08-13 | 2021-03-19 | 北京韩美药品有限公司 | Irak4抑制剂及其应用 |
| EP3858825A1 (en) | 2015-08-27 | 2021-08-04 | Pfizer Inc. | Bicyclic-fused heteroaryl compounds as irak4 modulators |
| US10059701B2 (en) | 2015-09-18 | 2018-08-28 | Merck Patent Gmbh | Heteroaryl compounds as IRAK inhibitors and uses thereof |
| MX2018002986A (es) | 2015-09-18 | 2018-05-02 | Merck Patent Gmbh | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos. |
| GB201518456D0 (en) | 2015-10-19 | 2015-12-02 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases |
| WO2017108723A2 (en) | 2015-12-22 | 2017-06-29 | F. Hoffmann-La Roche Ag | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS |
| WO2017108744A1 (de) | 2015-12-22 | 2017-06-29 | Bayer Pharma Aktiengesellschaft | Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| ES2904557T3 (es) | 2016-01-20 | 2022-04-05 | Biogen Ma Inc | Agentes inhibidores de irak4 |
| PL3448846T3 (pl) | 2016-04-29 | 2021-12-20 | Bayer Pharma Aktiengesellschaft | Synteza indazoli |
| WO2017205762A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017205769A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017205766A1 (en) | 2016-05-27 | 2017-11-30 | Pharmacyclics Llc | Inhibitors of interleukin-1 receptor-associated kinase |
| WO2017207385A1 (de) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituierte 3-methylindazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| US10710983B2 (en) | 2016-06-27 | 2020-07-14 | Rigel Pharmaceuticals, Inc. | 2,4-diamino-pyrimidine compounds and method for making and using the compounds |
| CN115531387A (zh) | 2016-10-26 | 2022-12-30 | 里格尔药品股份有限公司 | 用作irak抑制剂的吡唑酰胺化合物 |
| WO2018083085A1 (en) | 2016-11-02 | 2018-05-11 | F. Hoffmann-La Roche Ag | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS |
| JOP20180011A1 (ar) * | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| TWI842978B (zh) * | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
-
2019
- 2019-07-05 TW TW110107129A patent/TWI842978B/zh active
- 2019-07-05 TW TW108123710A patent/TWI721483B/zh active
- 2019-07-10 AR ARP190101944A patent/AR115731A1/es unknown
- 2019-07-11 ES ES19746263T patent/ES2981798T3/es active Active
- 2019-07-11 EP EP19746263.3A patent/EP3820872B1/en active Active
- 2019-07-11 IL IL279654A patent/IL279654B2/en unknown
- 2019-07-11 IL IL309267A patent/IL309267A/en unknown
- 2019-07-11 US US16/508,979 patent/US10875866B2/en active Active
- 2019-07-11 KR KR1020237032732A patent/KR20230144100A/ko not_active Application Discontinuation
- 2019-07-11 DK DK19746263.3T patent/DK3820872T3/da active
- 2019-07-11 EP EP24178268.9A patent/EP4403174A3/en active Pending
- 2019-07-11 AU AU2019302732A patent/AU2019302732B2/en active Active
- 2019-07-11 CN CN202311423711.5A patent/CN117683034A/zh active Pending
- 2019-07-11 UA UAA202008192A patent/UA127506C2/uk unknown
- 2019-07-11 PE PE2021000046A patent/PE20210404A1/es unknown
- 2019-07-11 LT LTEPPCT/US2019/041382T patent/LT3820872T/lt unknown
- 2019-07-11 NZ NZ771681A patent/NZ771681A/en unknown
- 2019-07-11 HR HRP20240811TT patent/HRP20240811T8/hr unknown
- 2019-07-11 WO PCT/US2019/041382 patent/WO2020014468A1/en active Application Filing
- 2019-07-11 CA CA3105485A patent/CA3105485C/en active Active
- 2019-07-11 FI FIEP19746263.3T patent/FI3820872T3/fi active
- 2019-07-11 MX MX2021000462A patent/MX2021000462A/es unknown
- 2019-07-11 EA EA202092858A patent/EA202092858A1/ru unknown
- 2019-07-11 CN CN201980046945.8A patent/CN112513044B/zh active Active
- 2019-07-11 PT PT197462633T patent/PT3820872T/pt unknown
- 2019-07-11 PL PL19746263.3T patent/PL3820872T3/pl unknown
- 2019-07-11 KR KR1020217003806A patent/KR102583817B1/ko active IP Right Grant
- 2019-07-11 CR CR20210014A patent/CR20210014A/es unknown
- 2019-07-11 SG SG11202013003VA patent/SG11202013003VA/en unknown
- 2019-07-11 JP JP2021500885A patent/JP7167298B2/ja active Active
- 2019-07-11 BR BR112020026675-2A patent/BR112020026675A2/pt unknown
- 2019-07-11 SI SI201930775T patent/SI3820872T1/sl unknown
-
2020
- 2020-12-03 US US17/110,734 patent/US11535622B2/en active Active
- 2020-12-23 PH PH12020552283A patent/PH12020552283A1/en unknown
-
2021
- 2021-01-05 ZA ZA2021/00259A patent/ZA202100259B/en unknown
- 2021-01-12 CO CONC2021/0000153A patent/CO2021000153A2/es unknown
- 2021-01-12 MX MX2024011542A patent/MX2024011542A/es unknown
- 2021-01-12 CL CL2021000086A patent/CL2021000086A1/es unknown
-
2022
- 2022-10-07 AU AU2022246450A patent/AU2022246450A1/en not_active Abandoned
- 2022-10-26 JP JP2022171477A patent/JP2022191496A/ja not_active Withdrawn
- 2022-11-23 US US18/058,559 patent/US20230257386A1/en active Pending
-
2024
- 2024-05-28 AU AU2024203567A patent/AU2024203567A1/en active Pending
- 2024-07-16 JP JP2024113659A patent/JP2024150556A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| ECSP20044709A (es) | Inhibidores de sarcómero cardíaco | |
| CL2022001392A1 (es) | Compuestos tricíclicos sustituidos | |
| ECSP24026637A (es) | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona | |
| UY37854A (es) | Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| UY37847A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| AR077292A1 (es) | Derivados de piperazin - quinolin sulfonamidas y composiciones farmaceuticas | |
| PE20210404A1 (es) | Derivados de pirrolo [1,2-b] piridazina | |
| CL2017003032A1 (es) | Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste | |
| AR102227A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| MA42341B2 (fr) | Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale | |
| CL2020002096A1 (es) | Inhibidores de arginasa y sus métodos de uso. | |
| PE20240930A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| CO2022008171A2 (es) | Derivado tricíclico de dihidroimidazopirimidona, método de preparación del mismo, composición farmacéutica y uso del mismo | |
| CO2019006220A2 (es) | Compuestos de pirazolopirimidina y métodos de uso de los mismos | |
| CL2023002616A1 (es) | Inhibidores del sarcómero cardíaco | |
| MY197742A (en) | Morphinan derivative | |
| CL2020002188A1 (es) | Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmacéutico. | |
| MA50093B1 (fr) | Composé pentacyclique | |
| CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| AR106475A1 (es) | Derivados de piridina o de pirimidina | |
| AR107937A1 (es) | Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer | |
| AR116428A1 (es) | Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo | |
| ECSP22027784A (es) | Derivados de 2azaespiro[3.4]octano como agonistas de m4 |